Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Type of study
Language
Publication year range
2.
J Cardiothorac Vasc Anesth ; 36(8 Pt A): 2819-2823, 2022 08.
Article in English | MEDLINE | ID: mdl-35525703

ABSTRACT

AN APPRECIATION of the utility of echocardiographic Doppler spectral profile analysis in diagnosing cardiac pathology and guiding surgical intervention more than justifies an investment in obtaining proficiency in these skills. Given the relatively low incidence of significant complications associated with transesophageal echocardiographic examination, the facile use of both spectral and color Doppler principles to diagnose unusual pathology is essential. Doppler modalities are used to characterize blood flow, pressure gradients, chamber dimensions, and other anatomic and physiological parameters. The authors present a case in which several Doppler principles were used to evaluate and diagnose the etiology of dyspnea and a high aortic valve gradient.


Subject(s)
Aortic Valve Stenosis , Heart Valve Prosthesis , Aortic Valve Stenosis/complications , Aortic Valve Stenosis/diagnostic imaging , Aortic Valve Stenosis/surgery , Dyspnea/diagnostic imaging , Dyspnea/etiology , Echocardiography, Doppler/methods , Echocardiography, Transesophageal/methods , Heart , Humans
3.
A A Pract ; 13(12): 478, 2019 12 15.
Article in English | MEDLINE | ID: mdl-31703003
4.
A A Pract ; 13(7): 271-273, 2019 Oct 01.
Article in English | MEDLINE | ID: mdl-31265446

ABSTRACT

Andexanet alfa is a recombinant factor Xa decoy molecule capable of reversing direct and indirect factor Xa-inhibiting anticoagulants. We present an adult patient on apixaban for nonvalvular atrial fibrillation who required urgent reoperative aortic surgery for an aortic root pseudoaneurysm. Apixaban was reversed with andexanet alfa. A second dose of andexanet alfa was required before surgical incision for persistently elevated antifactor Xa levels. Intraoperative management required use of cardiopulmonary bypass (CPB). No major adverse cardiovascular, cerebrovascular, hemorrhagic, or thromboembolic events were observed.


Subject(s)
Aneurysm, False/surgery , Antidotes/administration & dosage , Aorta, Thoracic/surgery , Factor Xa/administration & dosage , Recombinant Proteins/administration & dosage , Antidotes/therapeutic use , Cardiopulmonary Bypass , Factor Xa/therapeutic use , Humans , Middle Aged , Pyrazoles , Pyridones , Recombinant Proteins/therapeutic use , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...